Rina-S: Clinical Trials

3 trials of Rina-S, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Recruiting 3
Phase 11Recruiting 1

Follow Rina-S: new trials by email Literature Review of Rina-S trials Research Report on Rina-S

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
Rina-S - Gastrointestinal Cancers
Phase 2RecruitingGenmab1602026-05-112026-11-03
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Rina-S - Non-small Cell Lung Cancer (NSCLC)
Phase 2RecruitingGenmab2402026-01-302026-11-03
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Rina-S, Carboplatin, Bevacizumab - High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Phase 1 / Phase 2RecruitingGenmab9522022-12-072026-11-04

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Breast Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Mesothelioma (1)  ·  Ovarian Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)  ·  Uterine Neoplasms (1)

Sponsors

Genmab (3)

Countries

Japan (3)  ·  South Korea (3)  ·  United States (3)  ·  Australia (2)  ·  Belgium (2)  ·  China (2)  ·  France (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Hungary (1)  ·  Italy (1)  ·  Poland (1)  ·  United Kingdom (1)

NIH funding

2025 (2)